Y-mAbs Therapeutics (YMAB) Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Which has preferable earnings & valuation, YMAB or CRMD?

CorMedix has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$65.27M	3.47	-$95.57M	-$0.89	-5.83
CorMedix	$36.52K	5,447.63	-$29.70M	-$0.86	-4.22

Which has more risk and volatility, YMAB or CRMD?

Y-mAbs Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Does the media favor YMAB or CRMD?

In the previous week, Y-mAbs Therapeutics' average media sentiment score of 0.00 beat CorMedix's score of -0.27 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Y-mAbs Therapeutics	Neutral
CorMedix	Neutral

Do analysts recommend YMAB or CRMD?

Y-mAbs Therapeutics presently has a consensus target price of $12.63, indicating a potential upside of 143.26%. CorMedix has a consensus target price of $12.33, indicating a potential upside of 244.51%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Y-mAbs Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.18
CorMedix	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is YMAB or CRMD more profitable?

Y-mAbs Therapeutics has a net margin of -45.96% compared to CorMedix's net margin of -45,003.03%. Y-mAbs Therapeutics' return on equity of -36.37% beat CorMedix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-45.96%	-36.37%	-28.14%
CorMedix	-45,003.03%	-68.87%	-61.41%

Does the MarketBeat Community believe in YMAB or CRMD?

Y-mAbs Therapeutics received 105 more outperform votes than CorMedix when rated by MarketBeat users. Likewise, 59.04% of users gave Y-mAbs Therapeutics an outperform vote while only 50.00% of users gave CorMedix an outperform vote.

Company	Underperform	Outperform
Y-mAbs Therapeutics	Outperform Votes 111 59.04%	Underperform Votes 77 40.96%
CorMedix	Outperform Votes 6 50.00%	Underperform Votes 6 50.00%

Do insiders & institutionals believe in YMAB or CRMD?

45.5% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 35.0% of CorMedix shares are held by institutional investors. 21.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 3.6% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Y-mAbs Therapeutics beats CorMedix on 10 of the 17 factors compared between the two stocks.